Michael Matiop Aleu

Michael Matiop Aleu

Auto-generated profile, based on publicly available information

Michael Matiop Aleu

Department of Pharmaceutical Chemistry, Pharmacology, and Pharmacognosy, School of Pharmacy and Health Sciences United States International University‐Africa Nairobi Kenya

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
PDF file
SISamuel Inshutiyimana
Samuel Inshutiyimana
MAMichael Matiop Aleu
Michael Matiop Aleu
MAMustaf Aden Abdinoor
Mustaf Aden Abdinoor
MJMariyah Murtaza Janoowalla
Mariyah Murtaza Janoowalla
NNNorhayati Norhayati
Norhayati Norhayati
Although diloxanide is a drug of choice for treating asymptomatic amoebiasis, its mechanism of action (MOA) remains unclear. This review aims to shed light on the current understanding of the effectiveness and MOA of diloxanide in treating amoebiasis . It involves analysis of articles, retrieved from PubMed, Google Scholar and EBSCOhost, on diloxanide and the treatment of Entamoeba histolytica infection. Diloxanide is used in an ester form, which allows its high luminal concentration and greater efficacy than metronidazole in the management of asymptomatic amoebiasis. The current understanding of the action of diloxanide is based on its structural similarity to chloramphenicol at dichloroacetamide group. It acts against protein synthesis in E. histolytica trophozoites, blocking their conversion to more virulent and invasive cyst forms. Furthermore, it has a parasite clearance rate of 81–96% and treats amoebic abscesses when combined with metronidazole and chloroquine. Nevertheless, it is associated with adverse events such as flatulence, anorexia, headache and urticaria. Diloxanide is efficacious against amoebiasis but there is a need to explore its structure–activity relationship.The study suggests future directions, including novel drug formulations, diagnostic improvements, and combination regimens to enhance treatment outcomes and mitigate relapse associated with the use of diloxanide.

1 January 2025 in IET Collaborative Intelligent Manufacturing
Verified
Journal Article
Open access
SISamuel Inshutiyimana
Samuel Inshutiyimana
KRKush Rajeshbhai Rana
Kush Rajeshbhai Rana
FAFatuma Ali Abdullahi
Fatuma Ali Abdullahi
MAMichael Matiop Aleu
Michael Matiop Aleu
Artificial intelligence is transforming the pharmaceutical sector through improvement in critical processes such as quality assurance (QA). However, in Kenya, technical problems in QA processes, including in‐process quality control, equipment maintenance, and visual inspections exist. This paper aims to shed light on the potential of AI in improving pharmaceutical QA in Kenya and challenges associated with its integration. A literature search was thoroughly conducted by retrieving articles from Google Scholar. Articles and policy documents with information relevant to AI applications in QA, optimising pharmaceutical processes, and regulatory compliance in Kenya were reviewed and analysed. AI can improve efficiency and precision in various QA processes including warehousing, equipment maintenance, in‐process quality control, and visual inspections, among others. Significant challenges to AI incorporation in QA of Kenya's pharma companies include a lack of technical expertise and understanding of AI outcomes, high implementation costs and fear of losing jobs. There should be strengthened collaborations among government, pharmaceutical manufacturers, AI companies, and researchers to address skill‐based barriers and financial challenges.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
SISamuel Inshutiyimana
Samuel Inshutiyimana
PYPatel Dineshbhai Yesh
Patel Dineshbhai Yesh
MAMichael Matiop Aleu
Michael Matiop Aleu
ASAibekhanya Nkosana Sebata
Aibekhanya Nkosana Sebata
KAKenfa Ajumesi
Kenfa Ajumesi
Background: Type 2 diabetes mellitus (T2DM) refers to a chronic metabolic disorder that results from insulin resistance, leading to impaired insulin action and uncontrolled plasma glucose levels. Acalypha wilkesiana is among medicinal plants that are ethnobotanically used in the management of T2DM. However, there is a paucity of information on its antidiabetic potential. This review is aimed at providing a current understanding of the mechanism of action, potency, and safety of Acalypha wilkesiana in T2DM therapy. Methods: A narrative review was thoroughly conducted by searching Google Scholar and PubMed databases using a predefined combination of keywords. All gathered articles were reviewed for the content regarding T2DM, Acalypha wilkesiana , mechanism of action, and safety. A total of 44 articles were considered in this review. Results: Several experimental studies revealed that extracts of Acalypha wilkesiana inhibit α ‐glucosidase and α ‐amylase, which normally break down carbohydrates postprandially. Notably, the ethanolic root bark extracts of Acalypha wilkesiana have shown lower inhibitory concentrations compared to those of both the plant extracts in other solvents and the acarbose drug, emphasizing its greater potency. Additionally, the leaves of Acalypha wilkesiana have been reported to have no harmful effects on the red blood cells of diabetic rabbits and can even restore the alloxan‐induced impairment of pancreas and spleen cells. Conclusion: Acalypha wilkesiana demonstrates antihyperglycemic activity and can reverse the dysfunction of critical organs. It promises advances in the development of antihyperglycemic agents which are more efficacious and safer than synthetic agents. However, clinical trials should be conducted to establish human‐tailored doses, ensuring an improved safety profile of the plant in the treatment of T2DM.

21 July 2026 in Neuropsychopharmacology Reports
Verified
Journal Article
Open access
SISamuel Inshutiyimana
Samuel Inshutiyimana
KRKush Rajeshbhai Rana
Kush Rajeshbhai Rana
MAMichael Matiop Aleu
Michael Matiop Aleu
NBNaomi Bwalya
Naomi Bwalya
BNBonaventure Nsengimana
Bonaventure Nsengimana
OKOnesmas Kipkurui
Onesmas Kipkurui
Background: Nonadherence to antipsychotics affects nearly half of patients with schizophrenia, leading to rehospitalization, suicidality, and reduced quality of life. Optimizing treatment adherence is critical to prevent disease relapses, which can be life‐threatening. This review provides an updated status of innovative efforts in ensuring treatment adherence and the challenges associated. It also addresses future directions to improve treatment outcomes among patients with schizophrenia. Methods: A narrative review was thoroughly conducted by retrieving peer‐reviewed articles from PubMed, Google Scholar, ScienceDirect, and Web of Science. Articles relevant to the aim of the review and published in English were reviewed and analyzed. A total of 76 articles were included in the final report. Results: Digital pills have demonstrated adherence detection rates reaching above 95%. Wearable devices such as smart watches collect real‐time behavioral and physiological data such as sleep patterns, heart rate variability, and physical activity that reflect adherence or emerging relapse. These metrics enable clinicians to customize interventions according to the patient adherence profile, allowing shared decision‐making during treatment. Besides, the biomarker‐based monitoring system provides more precise tracking, thus reducing the risk of an unsuitable treatment switch. Aptamer‐based technologies also provide ultrasensitive and noninvasive adherence monitoring through the detection of antipsychotics in body fluids. Conclusion: Integration of wearable and biomarker data enables clinicians to make evidence‐based pharmacological decisions while treating schizophrenic patients. Artificial intelligence promises to facilitate this integration by forecasting medication lapses and suggesting personalized solutions. To fully revolutionize adherence in schizophrenia treatment, pharmacists, psychiatrists, bioengineers, and policymakers should collaborate to address ethical, infrastructural, and financial barriers present in this practice.